Evaluation of the plasma concentration of ponatinib in a chronic myeloid leukaemia patient with ponatinib intolerance.
Maiko AbumiyaNaoto TakahashiTomoko YoshiokaYoshihiro KameokaMasatomo MiuraPublished in: Journal of clinical pharmacy and therapeutics (2020)
Monitoring of the ponatinib plasma concentration led to safe and effective CML management in a patient with higher drug bioavailability.